MYC and triple-negative breast carcinoma: A second study from the same group reported that triple-negative breast cancer (TNBC) with elevated MYC expression displayed efficacy with CDK1 inhibition (purvalanol, dinaciclib, or siRNA), compared to lines with low MYC expression [187].